Please login to the form below

Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz

Post-marketing study shows increased risk of serious heart-related problems and cancer with Xeljanz. ... In addition, 122 patients receiving Xeljanz treatment developed cancer, versus 42 for those taking TNF inhibitors.

Latest news

Pfizer, Sanofi and others set to increase US drug prices in 2021

Pfizer, in particular, aims to raise prices on over 60 drugs by between 0.5% and 5%, with an approximate 5% increase on some blockbuster treatments including Xeljanz (tofacitinib) and cancer
Incyte’s JAK inhibitor cream clears second eczema trial

The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for
Skyrizi, Rinvoq help AbbVie weather Humira slowdown

Meanwhile, selective JAK inhibitor Rinvoq added another $33m from its first approval in rheumatoid arthritis, as it took on market leader Xeljanz (tofacitinib) from Pfizer, which showed the first signs of
Vyndaqel a bright spot as Pfizer comes under pressure

The company’s fourth-quarter results saw a 9% drop in revenues to $12.69bn, with breast cancer drug Ibrance (palbociclib) and Xeljanz (tofacitinib) for rheumatoid arthritis both growing but missing ... Ibrance was up 15% to $1.28bn in the quarter,
GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

This includes its CDK 4/6 inhibitor Ibrance (palbociclib), which grew by 27% to $1.3bn in the last quarter, and its fast-growing oral JAK inhibitor Xeljanz (tofacitinib).

More from news
Approximately 20 fully matching, plus 64 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

JAK inhibitors such as Xeljanz and Rinvoq.
20 for 2020 – Five pharma leaders to watch in 2020

to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance (palbociclib) and arthritis drug Xeljanz (tofacitinib), among others.
Pharma deals during September 2013

antibody (MAb) Actemra and Pfizer's JAK inhibitor Xeljanz.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

Webcast: Navigating new frontiers: Ways to find space in the future RA market

In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
Live webinar: Navigating new frontiers: Ways to find space in the future RA market

Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
Infographic: RA Perceptions

The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with
Brand leaders in RA will lose market share, predict rheumatologists

JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. . ... The EMA’s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

PMHub

Add my company

Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...